相似文献
1
A Metabolic Smorgasbord Drives and Sustains CSC Heterogeneity.
Cancers (Basel). 2023 Jan 5;15(2):343. doi: 10.3390/cancers15020343.
2
A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I.
Curr Mol Pharmacol. 2024;17(1):e060923220758. doi: 10.2174/1874467217666230906092236.
3
Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications.
Pharmacol Res. 2021 Jan;163:105320. doi: 10.1016/j.phrs.2020.105320. Epub 2020 Dec 1.
4
Therapy resistance mediated by cancer stem cells.
Semin Cancer Biol. 2018 Dec;53:156-167. doi: 10.1016/j.semcancer.2018.11.006. Epub 2018 Nov 22.
5
Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity.
Oncotarget. 2017 Oct 15;8(59):99223-99236. doi: 10.18632/oncotarget.21834. eCollection 2017 Nov 21.
6
Cancer stem cell hypothesis 2.0 in glioblastoma: Where are we now and where are we going?
Neuro Oncol. 2024 May 3;26(5):785-795. doi: 10.1093/neuonc/noae011.
7
Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting.
BMB Rep. 2017 Mar;50(3):117-125. doi: 10.5483/bmbrep.2017.50.3.222.
8
The role of cancer stem cells in tumor heterogeneity and resistance to therapy.
Can J Physiol Pharmacol. 2017 Jan;95(1):1-15. doi: 10.1139/cjpp-2016-0079. Epub 2016 Sep 3.
9
Pancreatic cancer stem cells--insights and perspectives.
Expert Opin Biol Ther. 2009 Oct;9(10):1271-8. doi: 10.1517/14712590903246362.
10
Cancer stem cells in small cell lung cancer.
Transl Lung Cancer Res. 2016 Feb;5(1):16-25. doi: 10.3978/j.issn.2218-6751.2016.01.01.
引用本文的文献
1
Safely Targeting Cancer, the Wound That Never Heals, Utilizing CBP/Beta-Catenin Antagonists.
Cancers (Basel). 2025 Apr 29;17(9):1503. doi: 10.3390/cancers17091503.
本文引用的文献
1
A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I.
Curr Mol Pharmacol. 2024;17(1):e060923220758. doi: 10.2174/1874467217666230906092236.
2
Oocytes maintain ROS-free mitochondrial metabolism by suppressing complex I.
Nature. 2022 Jul;607(7920):756-761. doi: 10.1038/s41586-022-04979-5. Epub 2022 Jul 20.
3
Taking the road less traveled - the therapeutic potential of CBP/β-catenin antagonists.
Expert Opin Ther Targets. 2021 Sep;25(9):701-719. doi: 10.1080/14728222.2021.1992386. Epub 2021 Oct 27.
4
The Metabolic Heterogeneity and Flexibility of Cancer Stem Cells.
Cancers (Basel). 2020 Sep 28;12(10):2780. doi: 10.3390/cancers12102780.
5
The Mode of Stem Cell Division Is Dependent on the Differential Interaction of β-Catenin with the Kat3 Coactivators CBP or p300.
Cancers (Basel). 2019 Jul 9;11(7):962. doi: 10.3390/cancers11070962.
6
Stem cell fate in cancer growth, progression and therapy resistance.
Nat Rev Cancer. 2018 Nov;18(11):669-680. doi: 10.1038/s41568-018-0056-x.
7
Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling.
Cell Metab. 2018 Jul 3;28(1):69-86.e6. doi: 10.1016/j.cmet.2018.06.006.
8
Hallmarks of cancer stem cell metabolism.
Br J Cancer. 2016 Jun 14;114(12):1305-12. doi: 10.1038/bjc.2016.152. Epub 2016 May 24.
9
CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells.
Oncogene. 2016 Jul 14;35(28):3705-17. doi: 10.1038/onc.2015.438. Epub 2015 Dec 14.
10
The metabolic landscape of cancer stem cells.
IUBMB Life. 2015 Sep;67(9):687-93. doi: 10.1002/iub.1426. Epub 2015 Sep 4.
Zotero 插件